Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of March 31, 2018 and December 31, 2017 are as follows:

			As of March 31, 2018			As of December 31, 2017
			(unaudited)
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Diagnostic assets:
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		18,351			18,351
Total			$	43,011		$	43,011
Diagnostic lab:
CLIA Lab		2.3	$	609		$	609
Accumulated Amortization			$	(11,328	)	$	(10,515	)
Net Carrying Value			$	32,292		$	33,105

Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

2018		2019		2020		2021		2022
$	3,252	$	5,292	$	5,292	$	4,908	$	2,987